mybacs: Funding, Investors & Team (Oct 2026)
mybacs is a Biotechnology company that focuses on the human microbiome and conducts both direct-to-consumer research. Our aim is to transform the intestinal healthcare market and enhance the overall well-being of our customers. We have a team of skilled pharmaceutical scientists and physicians dedicated to creating innovative and potent synbiotic supplements. These supplements are formulated with carefully chosen probiotic cultures, prebiotics, as well as minerals and vitamins personalized to meet the unique requirements of each customer.
mybacs has raised $5.9M across 1 funding round on record, the most recent a Series A of $5.9M announced in Oct 2023.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
mybacs Company Profile and Key Stats
Latest funding round on record: Oct 2023.
mybacs Funding Rounds
mybacs Founders and Leadership Team
Contact details for the mybacs team: 1 of 1 has an email address on file.
Start 14-day free trial →mybacs Funding Compared to Other Biotechnology Startups
mybacs' latest round of $5.9M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like mybacs in Biotechnology and Zug
Companies Similar to mybacs
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
mybacs Funding FAQs
What does mybacs do?
mybacs is a Biotechnology company that focuses on the human microbiome and conducts both direct-to-consumer research. Our aim is to transform the intestinal healthcare market and enhance the overall well-being of our customers. We have a team of skilled pharmaceutical scientists and physicians dedicated to creating innovative and potent synbiotic supplements. These supplements are formulated with carefully chosen probiotic cultures, prebiotics, as well as minerals and vitamins personalized to meet the unique requirements of each customer.
How much funding has mybacs raised?
mybacs has raised $5.9M across 1 round on record. The most recent is a Series A of $5.9M announced in Oct 2023.
When did mybacs last raise funding?
mybacs' most recent funding round on record is a Series A of $5.9M, announced in Oct 2023.
Who founded mybacs?
FundedIQ lists Sebastian Wahl (Founder) at mybacs.
Where is mybacs headquartered?
mybacs is based in Zug, Switzerland.
How many employees does mybacs have?
mybacs is in the 11-50 employee band.
How does mybacs' funding compare to other Biotechnology startups?
mybacs' latest round of $5.9M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's mybacs Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for mybacs is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.